The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT04634500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04634500
Other papers using this trial's data
  • Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial Diabetes & metabolism journal, 2023-11 DOI, PubMed 36756676, PMC10695710 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04634500. Randomized; double masking; primary purpose treatment. Start 2020-11-18 (actual); primary completion 2021-11-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
Acronym
ENHANCE-M
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
Dapagliflozin
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct04634500
Content hash
be59cb315e2d4a5987b472f4ad5248290f60d487c1a07a8fb76864f24ca8f056